始めましょう
ReutersReuters

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

Refinitiv1分未満で読めます
CYBN

Cybin Inc CYBN:

  • CYBIN ANNOUNCES ADDITIONAL U.S. PATENT SUPPORTING ITS CYB003 BREAKTHROUGH THERAPY PROGRAM IN PHASE 3 DEVELOPMENT FOR MAJOR DEPRESSIVE DISORDER

Reutersカナダ株米国株
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう

Reutersからその他のニュース